Ian Read, Pfizer’s new chief executive officer, has made changes to the company’s executive team. Mr. Read elevated his executive team to take over the responsibilities of his former position, overseeing the sales and marketing of certain prescription drug units. The team includes longtime employees Olivier Brandicourt and David Simmons. Mr. Brandicourt runs Pfizer’s prescription drugs business. Mr. Simmons was instrumental in the company’s expansion into emerging markets, such as China, aimed at increasing revenue.

R&D chief Mikael Dolsten, who came over from Wyeth, will remain in his position. Geno Germano, also from Wyeth, will join the company’s executive leadership team. He runs the business that sells oncology products and other medicines.

Chief financial officer Frank D’Amelio was also given control of manufacturing. Tony Maddaluna will be head of global manufacturing, reporting to Mr. D’Amelio. The unit was previously run by Nat Ricciardi, who is retiring in 2011 after 38 years with Pfizer.

Cavan Redmond will have expanded responsibilities. He currently runs Pfizer’s consumer and animal-health businesses. Mary McLeod, the head of human resources, is leaving the company. Chuck Hill, who had been running human resources for Mr. Read’s pharmaceutical sales and marketing operations, will succeed Ms. McLeod. Additionally, George Lorch has been elected as a new chairman of the board, succeeding Mr. Jeff Kindler, Pfizer’s previous chief executive officer.